Sibylla Biotech exploits a proprietary technological platform, a mix of physics, informatics and biology, able to: model the protein folding process, identify novel binding sites, and design molecules able to induce protein degradation (protein degraders) for targets that are currently non druggable.

The technology originates from a multidisciplinary collaboration among Istituto Nazionale di Fisica Nucleare, Università degli Studi di Trento, Fondazione Telethon ETS and Università degli Studi di Perugia.

Indaco Bio invested in Sibylla in October 2022 to further develop the technology and expand its pipeline.